Novel treatment shows early promise in difficult to treat Hodgkin lymphoma and T-cell lymphomas

A phase 1 trial of a new treatment called camidanlumab tesirine has found that this could be an effective option for people with lymphoma that has relapsed or is refractory after several previous courses of treatment.

Text that says Results

An early-phase trial of a new treatment called camidanlumab tesirine has produced promising response rates in people with lymphoma that has come back or not responded after several previous courses of treatment – people who typically have very limited treatment options.

Camidanlumab tesirine is an antibody-drug conjugate: an antibody joined to an anti-cancer drug. The antibody sticks to a protein called CD25, which is found on the surface of many lymphoma cells. It carries the drug straight to the lymphoma cells, wherever they are in the body.

The phase 1 trial included 133 people with Hodgkin or non-Hodgkin lymphoma. On average, the people who took part in the trial had had five previous courses of treatment, including 59 people who had had a stem cell transplant.

The trial found that camidanlumab tesirine produced high response rates in this difficult-to-treat group of people. The results were particularly encouraging in people with classical Hodgkin lymphoma or T-cell lymphomas. It is important to note that this is very early data and long-term follow-up isn’t available yet.

The treatment is now being studied further in ongoing trials.

To find out more about clinical trials for lymphoma, or to search for a trial that might be suitable for you, visit Lymphoma TrialsLink.

21 June 2021